

Cadaveric Oral Fluid Quick Reference Guide

OraQuick® Ebola Rapid Antigen Test

The OraQuick® Ebola Rapid Antigen Test is intended for the qualitative detection of antigens from viruses within the *Ebolavirus* genus in whole blood from individuals with epidemiological risk factors with signs and symptoms of EVD or cadaveric oral fluid from recently deceased individuals with epidemiological risk factors who are suspected to have died of EVD. For the full intended use, limitations, and warnings see the instructions for use inside the box.

POUCH CONTENTS: 1 developer vial, 1 device and 1 absorbent packet

STEP 1a. – Specimen Collection 1,2,3 Direct Specimen Collection


For direct collection, swab the cadaver using the flat pad of the device. If direct collection from the soft palate is not possible due to rigor mortis, collect sample from the gum line. After collection go to Step 2.





Collect sample from the soft palate (back of the oral cavity) using the flat pad of the device.

OR



OR

STEP 1b. – Specimen Collection 1,2,3 Viral Transport Media

For specimen collection in viral transport media follow instruction of the Swab/Transport media manufacturer. Prior to testing, mix the transport media tube gently by inversion several times. Store at 2° - 25° C (36° - 77° F) for transport. If sample cannot be tested within 48 hours of collection, store specimen at -70° C (-94° F).



Remove the collection swab from the tube. Using a calibrated laboratory pipette, slowly draw up 20µL of viral transport media sample.

NOTE: If a bubble is present, discard the sample and obtain a new sample using a new pipette tip.



Deposit the cadaveric sample into the sample port on the device. Go to Step 2.

STEP 2. - Perform the Test

Insert device into developer vial





Purple fluid travels through the Result Window



DO NOT remove the device from the developer vial while the test is running.

STEP 3. - Read Results

Positive results may be interpreted as soon as lines are visible in the Test (T) Zone and the Control (C) Zone and have been observed as early as 4 minutes. Negative results **MUST** be read 30 minutes after inserting the device into the Developer vial. To report a device problem, contact OraSure Technologies Customer Service (1-800-orasure) within the US or +(001) 610-882-1820 for outside the US. You can also go to http://www.orasure.com/contact/contact-customer-service.asp.

Negative: Line in C Zone

Invalid: Repeat with a Fresh Sample



Positive: Lines in C and T Zones



- A Positive test result means that Ebola Antigen has been detected in the specimen. The cadaver is presumed positive for Ebola.
- Individuals with a positive result with the OraQuick^e Ebola Rapid Antigen Test should, in accordance with CDC and WHO recommendations, be subjected to safe and dignified burial procedure. Contacts of an Ebola positive cadaver should be identified and followed up on.

Order

Information and Description

1001-0509 Box of 25 tests 1001-0508 Kit Controls 1001-0537 Visual Reference Panel 1 See "Universal Precautions," CDC, MMWR, 1988; 37(24):377-388. 2 Centers for Disease Control and Prevention and World Health Organization. Infection Control for Viral Haemorrhagic Fevers in the African Health Care Setting, Atlanta, Centers for Disease Control and Prevention 1981-1198. 3 [Infermation For Health Care Workship of the Heal

Please refer to the package insert for complete information and instructions on the proper use of the OraQuick® Ebola Rapid Antigen Test.

©2019 OraSure Technologies, Inc. U.S. This product is covered by one or more patents. See www.OraSure.com/patents. OraQuick* Ebola is a registered trademark of OraSure Technologies, Inc.

OraSure Technologies

220 East First Street Bethlehem, PA 18015 USA **phone:** 800.ORASURE **web:** www.OraSure.com